Phase 1Data readout

GD2-SADA

Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma

YMABY-mAbs Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: GD2-SADA
Development stage: Phase 1
Event type: Data readout
Indication: Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for GD2-SADA in Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma. The expected timing is based on the latest available company guidance and may change.

Development notes

Trial 1001. 4/5/23- 1st patient dosed. 03/24- 1st cohort treated. 5/28/25- Part A completed & reported data at R&D. Initiate Bridge study (Part 2A) in H1 2026 with data in H2 2026; initiate Part B in H1 2027 with data in H2 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source